Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk

NCT07374718 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

468

Enrollment

OTHER

Sponsor class

Conditions

Acute Coronary Syndrome (ACS)
High Bleeding Risk(HBR)
Coronary Artery Disease (CAD)

Interventions

DEVICE: IVUS-guided BioFreedomTM Drug-Coated Stent Implantation + 1-Month DAPT Followed by 11-Month P2Y12 Inhibitor Monotherapy
DEVICE: Angiography-guided Conventional Drug-Eluting Stent Implantation + 12-Month Dual Antiplatelet Therapy (Aspirin + P2Y12 Inhibitor)

Sponsor

Shenyang Northern Hospital

Collaborators

[object Object]